Table 1.

Clinical characteristics of the first study population

Table 1	PE+ N=44		PE− N= 65		P^*
Vital signs and demographics	Mean or N	Standard deviation or %	Mean or N	Standard deviation or %	P^*
Age, years	50	16	58	18	0.07
Body Mass Index	31.9	8.2	28.9	7.6	0.16
SaO2, %	97	2	97	2	0.90
Systolic blood pressure, mm Hg	116	13	135	18	<0.001
Heart Rate, beats/min	94	21	89	18	0.46
Caucasian race	20	45%	44	68%	0.02
Black race	16	36%	18	28%	0.34
Female gender	26	59%	34	52%	0.48
Symptoms
Syncope	2	5%	2	3%	0.69
Pleuritic chest pain	20	48%	17	26%	0.04
Dyspnea	25	56%	35	54%	0.76
Hemoptysis	0	0%	2	3%	0.24
Cough	11	25%	27	42%	0.08
Limb swelling	10	23%	8	12%	0.15
Risk Factors^**
Prior stroke	0	0%	2	3%	0.24
Recent surgery	6	14%	10	15%	0.80
Heart failure	4	9%	8	12%	0.60
Bed rest >72h	10	23%	15	23%	0.97
Prior DVT without PE	8	18%	7	10%	0.27
Active connective tissue disease	1	2%	6	9%	0.15
Known thrombophilia	1	2%	0	0%	0.22
Active malignancy	5	11%	6	9%	0.72
Sickle cell disease	0	0%	1	2%	0.41
Anemia	3	7%	5	8%	0.86
Diabetes	4	9%	13	20%	0.12
Focal Infection	0	0%	5	8%	0.06
Current estrogen use	6	13%	3	5%	0.09
History of COPD	1	2%	6	9%	0.15
History of Asthma	5	12%	13	20%	0.23
Never smoked	30	68%	47	72%	0.64
Aspirin use in past 7 days	19	43%	27	42%	0.86

P values from unpaired t-test or Chi-Square

^**

Prior history requiring treatment; reported by patient or from documented past medical history at time of diagnosis